View Rule
View EO 12866 Meetings | Printer-Friendly Version Download RIN Data in XML |
DOJ/DEA | RIN: 1117-AB71 | Publication ID: Fall 2023 |
Title: Medical Missions | |
Abstract:
DEA proposes to create a new regulation to govern medical missions as well as amend existing to allow practitioners engaged in medical missions to export controlled substances as a coincident activity to the dispensing business activity. DEA has historically granted Medical Mission Waiver Letters, authorizing practitioners to export Schedule II-V controlled substances to a foreign country in furtherance of a medical mission. Because the Controlled Substances Import-Export Act (the non-domestic portion of the CSA) contains specific statutory export requirements that cannot be waived, and because DEA is prohibited from issuing improper guidance, it is necessary to regulate and clarify the application and recordkeeping requirements for medical missions. |
|
Agency: Department of Justice(DOJ) | Priority: Substantive, Nonsignificant |
RIN Status: Previously published in the Unified Agenda | Agenda Stage of Rulemaking: Proposed Rule Stage |
Major: No | Unfunded Mandates: No |
CFR Citation: 21 CFR 1301 | |
Legal Authority: 21 U.S.C. 821, 827, 871(b) |
Legal Deadline:
None |
||||||
Timetable:
|
Additional Information: DEA docket number 754 | |
Regulatory Flexibility Analysis Required: No | Government Levels Affected: None |
Small Entities Affected: Organizations | Federalism: No |
Included in the Regulatory Plan: No | |
RIN Information URL: DPW@dea.gov | Public Comment URL: www.regulations.gov |
RIN Data Printed in the FR: No | |
Agency Contact: Scott A. Brinks Section Chief, Regulatory Drafting and Support Section, Diversion Control Division Department of Justice Drug Enforcement Administration 8701 Morrissette Drive, Springfield, VA 22152 Phone:571 362-8209 Email: scott.a.brinks@dea.gov |